Reduced Cost of Genome Sequencing Expected to Surge up Market Demand for Cancer Genome Sequencing

Cancer genome process is something which helps in detecting the entire RNA and DNA structure and sequencing of tumorous cells, on the basis of an individual heterogeneous or homogeneous group of cancer cells. It also figures out the micro environment of affected cells, metastatic cancer sites, or distant or adjacent unaffected tissues. According to Transparency Market Research (TMR) the global cancer genome sequencing market is anticipated to flourish noticeably within the forecast period from 2015 to 2023.

The gene sequencing for cancer has a few favorable circumstances over conventional methodologies which incorporate the capacity to carry out entire gene sequencing in single test coupled with the identifying duplicate number modifications, translocations, and far reaching base substitutions in all the nearby cancer cells. The low cost related with entire genome sequencing and total time needed to play out the sequencing has definitely decreased in past few years. Factors supporting the cancer genome sequencing envelop complete perspective of entire genome, capacity encompass huge changes, and irrelevancy of the requirement of having any earlier information about the patient health history and status of the current ailment. Such potential development attributors are probably going to drive the demand for quality sequencing-based cancer treatment in coming few years. High procedural expenses and tedious understanding of large datasets are some of the leading restrictions that are expected to hamper the market growth. A contrasting option to the entire genome sequencing is the focused on quality sequencing strategy that is comparatively less expensive, with simple outcomes elucidation and high sensitivity for uncommon clones.

Based on geography the market is segregated into Europe, Asia Pacific, North America, and Rest of the World (RoW). North America regional market incorporates Canada and the U.S. which shape the significant revenue generator nations, due to improvement in gene therapy-based cancer treatment. Beckman Coulter Genomics, Illumina, Inc., BGI Americas Corporation, and SeqWright are some of the key players in the global market.

Request a Brochure of the Report @

Leave a Reply